ACCELERATOR PRODUCTION OF CU 64 FOR PET AND RADIOTHERAPY

该项目的目标是开发一个自动化系统， 使用小的生物医学生产高比活度铜-64 加速器铜-64（Tau 1/2=12.7 hr）是一种中等寿命的 正电子发射放射性核素，其是用于正电子的有用的放射性示踪剂， 发射断层扫描（PET）以及有前途的放射治疗剂， 癌症的治疗铜-64目前是反应堆生产的， 因为它只能在少量的反应器设施中生产， 其供应极为有限。 在第一阶段进行的实验表明，铜-64的高产率 具有高比活度和放射化学纯度， 使用常规PET回旋加速器或更低的回旋加速器的64 Ni（p，n）64 Cu反应 能量直线加速器在第二阶段，一个自动化的目标和 放射化学处理系统将开发用于生产和 - 纯化成像所需量的铜-64， 放疗 该系统的可用性将允许使用PET来诊断 生理条件，不能与短寿命的研究 正电子发射放射性核素，并将使广泛使用 铜标记的治疗剂。铜-64的长半衰期 还允许将治疗剂和成像剂分布到部位 不具备同位素生产能力。 拟议的商业应用：铜-64生产系统 在这个项目中开发的将立即引起研究人员的兴趣 利用小型生物医学回旋加速器和现有的回旋加速器， 放射性药物设施。现场提供64 Cu 生产系统将在发展中发挥重要作用 使用铜标记化合物的成像和放射治疗方案。

The goal of this project is to develop an automated system for the production of high specific activity copper-64 using small biomedical accelerators. Copper-64 (Tau 1/2=12.7 hr) is an intermediate-lived positron-emitting radionuclide which is a useful radiotracer for positron emission tomography (PET) as well as a promising radiotherapy agent for the treatment of cancer. Copper-64 is currently reactor produced, and, because it can only be produced at a small number of reactor facilities, its availability is extremely limited. Experiments conducted in Phase I showed that high yields of copper-64 with high specific activity and radiochemical purity can be produced via the 64Ni(p,n)64Cu reaction using conventional PET cyclotrons or low energy linear accelerators. In Phase II, an automated target and radiochemical processing system will be developed for the production and purification of copper-64 in the quantities required for imaging and radiotherapy. The availability of this system will allow the use of PET to diagnose physiological conditions which cannot be studied with the short-lived positron-emitting radionuclides and will make possible the widespread use of Cu-labeled therapeutic agents. The long half-life of copper-64 will also allow the distribution of therapeutic and imaging agents to sites that do not have isotope production capabilities. PROPOSED COMMERCIAL APPLICATION: The copper-64 production system developed in this program will be of immediate interest to researchers having access to small biomedical cyclotrons and to existing cyclotron- based radiopharmacy facilities. The availability of an on-site 64Cu production system will play an important role in the development of imaging and radiotherapy protocols using copper-labeled compounds.